Abstract 1629P
Background
The management of pancreatic adenocarcinoma continues to be challenging. Surgical resection is the only modality for a cure, with an overall survival rate of 10–20% at 5 years. However, only 20% of the patients are surgical candidates because of locally advanced disease or systemic stage at presentation.
Methods
A phase II clinical trial was carried out on 50 patients with previously untreated locally advanced, surgically unresectable pancreatic adenocarcinoma. Patients had ECOG PS 0 or 1 and adequate hematologic, renal, and hepatic function. They arranged to receive 3 cycles of modified FOLFIRINOX prior to CCRT, with losartan taken orally every day followed by chemoradiotherapy.
Results
Response after completion CCRT was assessed. 6% of patients achieved complete response. 38% of the patients had a partial response, while twenty-four patients (48%) had stable disease and 8% had progressive disease. Of the 50 patients, thirteen (26%) underwent surgery, with R0 resection achieved in 6 of 13 patients. Median follow-up period was 20.25 months (range, 6.0-34.5). The median PFS was 12 months (95% CI, 9.647 – 14.353), while Median OS was 21 months (95% CI, (10.200–31.800). The patients who underwent resection had longer survival 24 months (95% CI, (16.363 – 27.637) compared to those who did not undergo resection; mean OS was 14 months (95% CI, (9.205 – 18.795)). (P=0.271). The patients who achieved CR after modified Folforinox-losartan had a longer median OS of 33 months (95% CI, 19.918 – 46.082) compared to patients who had PR and SD, each had median OS of 13 months (95% CI, 6.768 – 19.232), (11.718 – 14.282) respectively (P=0.040*). The patients who achieved CR after CCRT had longer OS (NR) compared to those who had PR, SD and PD. median OS was 24, 14 and 8 months, respectively (95% CI, 6.761 – 41.239), (11.022 – 16.978), and (95% CI, 4.080 – 11.920) (P=<0.001*). The patients who achieved CR after CCRT had longer PFS (NR) compared to those who had PR, SD and PD. Median PFS was 24 (95% CI, 13.191 – 34.809), 10(95% CI, 4.973 – 15.027) and 5 (95% CI,4.823-5.124) months, respectively (P=<0.001*).
Conclusions
Induction chemotherapy with modified-FOLFIRINOX-losartan, followed by CCRT improved patient outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Menoufia University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1579P - Gender differences and worse metastatic survival outcomes in young adult patients with oesophagogastric cancer: 12-year data from a Czech comprehensive cancer center
Presenter: Tomás Sokop
Session: Poster session 22
1580P - Early onset oesophageal adenocarcinoma: A separate biological entity?
Presenter: Dharmesh Valand
Session: Poster session 22
1581P - Total neoadjuvant chemotherapy with FOLFIRINOX regimen in patients with resectable locally advanced gastric and gastroesophageal junction cancer
Presenter: Maria Sedova
Session: Poster session 22
1582P - Gastroesophageal adenocarcinoma in young adults: Retrospective analysis of clinical and molecular features
Presenter: Daniel Acosta Eyzaguirre
Session: Poster session 22
1583P - Intraperitoneal chemotherapy for peritoneal metastases of gastric origin: A systematic review and meta-analysis
Presenter: Niels Guchelaar
Session: Poster session 22
1585P - The impact of platinum-induced peripheral neuropathy (PN) in first-line treatment on PN and efficacy in second-line paclitaxel (PTX)-based chemotherapy for unresectable advanced gastric cancer (AGC): A prospective observational multicenter study - IVY study
Presenter: Yoshiyasu Kono
Session: Poster session 22
1587P - Analysis of survival outcomes according to start timing of adjuvant chemotherapy in patients with gastric cancer: A retrospective nationwide cohort study
Presenter: Tae-Hwan Kim
Session: Poster session 22
1588P - Analysis of risk factors of anastomotic leakage after minimally invasive esophagectomy with circular cervical anastomosis
Presenter: ming lu
Session: Poster session 22